SNGX Stock Overview
Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States.
Soligenix, Inc. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$0.56|
|52 Week High||US$1.00|
|52 Week Low||US$0.38|
|1 Month Change||-15.16%|
|3 Month Change||-22.22%|
|1 Year Change||-30.00%|
|3 Year Change||-52.54%|
|5 Year Change||-71.72%|
|Change since IPO||-99.63%|
Recent News & Updates
Soligenix: A Biotech Bargain Ready To File For Approval In Cutaneous T-Cell LymphomaOct 05
U.S. FDA awards $2.6M grant for expanded study of Soligenix's HyBryte for skin cancerSep 12
Is Soligenix (NASDAQ:SNGX) Using Debt Sensibly?Sep 06
Is Soligenix (NASDAQ:SNGX) Using Debt Sensibly?Apr 22
Is Soligenix (NASDAQ:SNGX) Using Too Much Debt?Jan 03
Shareholders May Find It Hard To Justify Increasing Soligenix, Inc.'s (NASDAQ:SNGX) CEO Compensation For NowSep 17
Health Check: How Prudently Does Soligenix (NASDAQ:SNGX) Use Debt?Aug 30
Is Soligenix (NASDAQ:SNGX) Weighed On By Its Debt Load?May 08
What Type Of Returns Would Soligenix's(NASDAQ:SNGX) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?Mar 16
Why Soligenix's (NASDAQ:SNGX) CEO Pay MattersNov 20
|SNGX||US Biotechs||US Market|
Return vs Industry: SNGX underperformed the US Biotechs industry which returned -7.4% over the past year.
Return vs Market: SNGX underperformed the US Market which returned -14.9% over the past year.
|SNGX Average Weekly Movement||9.3%|
|Biotechs Industry Average Movement||11.2%|
|Market Average Movement||7.4%|
|10% most volatile stocks in US Market||15.7%|
|10% least volatile stocks in US Market||3.3%|
Stable Share Price: SNGX is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: SNGX's weekly volatility (9%) has been stable over the past year.
About the Company
Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. It operates in two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of treat cutaneous T-cell lymphoma; and SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer.
Soligenix, Inc. Fundamentals Summary
|SNGX fundamental statistics|
Is SNGX overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|SNGX income statement (TTM)|
|Cost of Revenue||US$650.66k|
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.34|
|Net Profit Margin||-1,717.96%|
How did SNGX perform over the long term?See historical performance and comparison